FIGURE 7.
HT combined with PLB therapy reshapes the immune microenvironment of pancreatic cancer in mice. The mice with orthotopic pancreatic tumor received HT combined with PLB (HT 200 mg/kg, PLB 1 mg/kg) and normal saline intraperitoneal treatment for 10 days. Representative tumors in vivo (A), and the tumor weight was compared (n = 4 in each group) (B) (*p < 0.05, **p < 0.01). Tumor tissues infiltrating-MDSCs (n = 3 in each group) (C,D), CD4+ (n = 4 in each group) and CD8+ T cells (n = 3 in each group) (E,F), M1 macrophages (n = 3 in each group) (G,H) in the control group and the combination therapy group were analyzed and compared (*p < 0.05, **p < 0.01).